Pocket Paks, each containing 2 Elemin Mineral Tablets and 1 G & J Multiple Vitamin Tablet."

NATURE OF CHARGE: Misbranding, Section 502 (f) (1), the label of the article failed to bear directions for use in the treatment of ulcers, high blood pressure, arthritis, diabetes, polio, infantile paralysis, cancer, dormant glands, migraine headache, allergic reactions, thyroid trouble, and diarrhea, which were the conditions for which the article was intended and offered in oral statements made on November 4, 1953, by Roy M. Buck, operator of G & J Distributors, while promoting the sale of the article. The article was misbranded while held for sale after shipment in interstate commerce.

DISPOSITION: May 4, 1954. Default decree of condemnation and destruction.

4368. Misbranding of Nu-Mineral capsules. U. S. v. 3 Cases * * *. (F. D. C. No. 36350. Sample No. 82454–L.)

LIBEL FILED: January 19, 1954, Western District of Pennsylvania.

ALLEGED SHIPMENT: On or about November 28, 1953, from Clarksburg, W. Va. This was a return shipment.

PRODUCT: 3 cases, each containing 216 42-capsule bottles, of *Nu-Mineral capsules* at Sharon, Pa.

LABEL, IN PART: (Bottle) "Nu-Mineral Three Capsules Supply Dicalcium Phosphate, USP ..... 975 mgm. 30% Ferrous Sulfate, Dried, USP ..... 135 mg. 400% Potassium Iodide, USP ..... .45 mg. 300% Manganese Sulfate, H2O, CP ..... 4.5 mg. Cobalt Nitrate, 6 H2O, CP ..... 1.5 mg. Sodium Molybdate, 2 H2O, CP ..... 3.0 mg. Copper Sulfate, USP ..... 3.0 mg. Zinc Sulfate, USP ..... 4.2 mg. Magnesium Sulfate, USP ..... 97.5 mg. Aloin, USP ..... 8. mg. Vitamin B-12, USP ..... 3 mcgm. Distributed by Penn-Art Products, Sharon, Pa."

NATURE OF CHARGE: Misbranding, Section 502 (f) (1), the labeling of the article failed to bear adequate directions for use in the treatment of stomach ailments, weak kidneys, rheumatic pains, arthritis, neuritis, headaches, toxins, bloating, weak back, lumbago, back pains, lack of vitality, poor appetite, atonic constipation, spastic constipation, paleness, anemia, and weak eyes, which were the conditions for which the article was offered in advertising sponsored by the distributor, Penn-Art Products.

DISPOSITION: March 12, 1954. Default decree of condemnation. The court ordered that the product be delivered to a local hospital.

DRUGS ACTIONABLE BECAUSE OF DEVIATION FROM OFFICIAL OR OWN STANDARDS

4369. Adulteration and misbranding of Dexadex tablets. U. S. v. 437 Bottles * * *. (F. D. C. No. 36427. Sample No. 84339–L.)

LIBEL FILED: March 5, 1954, Eastern District of Pennsylvania.

ALLEGED SHIPMENT: On or about February 20, 1953, by Strong, Cobb & Co., Inc., from Cleveland, Ohio.

PRODUCT: 437 bottles of *Dexadex tablets* at Philadelphia, Pa. Analysis showed that the product contained 6.2 milligrams of dextro-amphetamine sulfate per tablet.

LABEL, IN PART: (Bottle) "Cabot 100 Tablets Dexadex * * * Each Tablet contains Dextro-Amphetamine Sulfate 10 mg."

NATURE OF CHARGE: Adulteration, Section 501 (c), the strength of the article differed from that which it was represented to possess, namely, 10 milligrams of dextro-amphetamine sulfate per tablet.

Misbranding, Section 502 (a), the label statement "Each Tablet contains Dextro-Amphetamine Sulfate 10 mg." was false and misleading as applied to a product containing less than the declared amount of dextro-amphetamine sulfate per tablet.

DISPOSITION: May 13, 1954. Default decree of condemnation. The court ordered that the product be delivered to a charitable institution.

4370. Adulteration of suprarenin tablets and procaine hydrochloride and epinephrine tablets. U. S. v. 12,473 Boxes, etc. (F. D. C. No. 36450. Sample Nos. 52638–L, 52639–L, 52641–L.)

LIBEL FILED: March 16, 1954, District of New Jersey.

ALLEGED SHIPMENT: During 1946, from various places outside the State of New Jersey.

PRODUCT: 12,473 boxes, each containing 5 vials, of *suprarenin tablets*, and 20,000 boxes, each containing 5 vials, and 6,300 boxes, each containing 10 vials, of *procaine hydrochloride and epinephrine tablets*, at Jersey City, N. J.

Analysis disclosed that the *suprarenin tablets* contained approximately 57.8 percent of the declared amount of epinephrine, and that the 20,000-box lot and the 6,300-box lot of the *procaine hydrochloride and epinephrine tablets* contained 75 percent and 52 percent, respectively, of the declared amount of epinephrine.

LABEL, IN PART: (Vial) "0.001 Gm. 20 Tablets * * * Suprarenin * * * Brand of Epinephrine (Synthetic) Each tablet contains Suprarenin Bitartrate 0.00182 Gm. equivalent to Suprarenin 0.001 Gm. (1/65 grain)," "20 Soluble Hypodermic Tablets Procaine Hydrochloride And Epinephrine Procaine Hydrochloride, 0.02 Gm.; Epinephrine 0.00005 Gm.," and "20 Tablets #20 Procaine, HCl (USP) 1/3 Grain (0.02 Gm.) Epinephrine 1/1200 Grain (0.00005 Gm.)."

NATURE OF CHARGE: Adulteration, Section 501 (c), the strengths of the articles differed from that which they purported and were represented to possess since the article in the 12,473-box lot contained less than 0.001 gram (1/65 grain) of epinephrine per tablet; the article in the 20,000-box lot contained less than 0.00005 gram of epinephrine per tablet; and the article in the 6,300-box lot contained less than 1/1200 grain (0.00005 gram) of epinephrine per tablet. The articles were adulterated while held for sale after shipment in interstate commerce.

DISPOSITION: April 27, 1954. Default decree of condemnation and destruction.

4371. Adulteration of Special Formula ampuls. U. S. v. 1,141 Ampuls * * *. (F. D. C. No. 36226. Sample No. 82548–L.)

LIBEL FILED: January 4, 1954, Western District of New York.

ALLEGED SHIPMENT: On or about November 20, 1953, by the Vitamix Corp., from Philadelphia, Pa.

PRODUCT: 1,141 *Special Formula ampuls* at Rochester, N. Y.

LABEL, IN PART: "5 cc. Amps. Special Formula Each 5 cc. contains: Iron Cacodylate 0.03 gm. Emetine HCl 0.06 gm. In physiological salt solution * * * For Intravenous Use."